Clinical Trial Update: Safety and Efficacy of Dapagliflozin in Asian T2DM Subjects With Inadequate Glycemic Control on Metformin/Saxagliptin [Phase 3]

View source ↗

Summary

Phase 3 trial update on dapagliflozin for Asian adults with type 2 diabetes inadequately controlled on metformin/saxagliptin; study terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Dapagliflozin (dapagliflozin)

Snippet

Sponsor: AstraZeneca | Conditions: Type 2 Diabetes Mellitus | Phase 3 | Status: TERMINATED